Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,937,200 | 3,916,300 | 3,105,900 | 3,491,300 | 3,395,100 |
| Marketable Securities | 6,990,500 | 5,043,400 | 4,636,400 | 3,530,400 | 4,171,300 |
| Receivables | 5,121,300 | 5,118,600 | 5,328,700 | 5,548,300 | 5,161,400 |
| Inventories | 2,507,700 | 2,424,700 | 2,401,900 | 2,412,200 | 2,218,500 |
| TOTAL | $16,923,000 | $16,909,200 | $15,884,100 | $15,428,600 | $15,529,900 |
| Non-Current Assets | |||||
| PPE Net | 3,922,600 | 3,880,900 | 3,763,000 | 3,704,200 | 3,637,700 |
| Investments And Advances | 6,327,200 | 6,066,600 | 6,591,800 | 5,968,600 | 6,415,900 |
| Intangibles | 953,000 | 928,700 | 915,500 | 804,100 | 0 |
| Other Non-Current Assets | 2,531,700 | 2,274,500 | 2,060,100 | 1,772,300 | 1,622,300 |
| TOTAL | $13,734,500 | $13,150,700 | $13,330,400 | $12,249,200 | $11,675,900 |
| Total Assets | $30,657,500 | $30,059,900 | $29,214,500 | $27,677,800 | $27,205,800 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 547,300 | 599,500 | 589,200 | 535,600 | 534,200 |
| Other current liabilities | 2,176,000 | 2,074,300 | 2,074,200 | 1,796,400 | 1,933,400 |
| TOTAL | $3,104,400 | $3,100,100 | $3,141,300 | $2,879,200 | $3,033,900 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,982,200 | 1,981,800 | 1,981,400 | 1,981,100 | 1,980,700 |
| Deferred Revenues | 381,100 | 426,300 | 477,900 | 547,200 | 566,300 |
| aiOther Non-Current Liabilities | 716,800 | 677,300 | 638,000 | 598,600 | 724,700 |
| TOTAL | $3,535,200 | $3,464,600 | $3,409,200 | $3,359,800 | $3,484,100 |
| Total Liabilities | $6,639,600 | $6,564,700 | $6,550,500 | $6,239,000 | $6,518,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 108,559 | 109,710 | 109,326 | 108,902 | 109,008 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 25,092,900 | 24,124,500 | 23,306,700 | 22,109,600 | 20,793,900 |
| Other shareholders' equity | -197,600 | -181,100 | -239,100 | -275,100 | -223,400 |
| TOTAL | $24,017,900 | $23,495,200 | $22,664,000 | $21,438,800 | $20,687,800 |
| Total Liabilities And Equity | $30,657,500 | $30,059,900 | $29,214,500 | $27,677,800 | $27,205,800 |